Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

New discovery sparks hope of safer dosage of Warfarin

17.05.2005


The blood-thinning drug Warfarin tops the list of drug side-effects in Sweden. Patient sensitivity to Warfarin varies, which can lead to over-dosage and in certain cases to death. A study led by Mia Wadelius at Uppsala University in Sweden, together with researchers in Cambridge, indicates that two genes may be the explanation. The findings are being published in the latest issue of The Pharmacogenomics Journal.



Warfarin is used to prevent blood clots, but a side-effect can be severe, even fatal, bleeding. In Sweden since the 1960s more fatal side-effects have been reported from Warfarin than for any other drug. Of the 118 deaths reported in connection with drug treatment in Sweden last year, nearly half involved bleeding from Warfarin.

There is still no good alternative to Warfarin in cases of blood clots or heart or valve diseases. Every year 70,000 patients in Sweden are treated with Warfarin. All patients receive the same dose the first few days, then the dosage is determined by a test of the capacity of the blood to coagulate. The differences are great in how much Warfarin patients need to attain an effect. One patient can require 20 times the dose needed by another patient.


The Uppsala University Section for Clinical Pharmacology is carrying out a pharmacogenetic study in collaboration with the Sanger Institute in Cambridge, England. The findings show that hereditary variations in two genes, together with the patient’s age, weight, disease, and other medicines, explain nearly 60 percent of the variations in dosage. One of the genes is called the vitamin-K-reductase gene and was discovered by two U.S. research teams last year. The other gene is the gene for the enzyme cytochrome P450 2C9, which governs the degradation of Warfarin and has long been known. Now Mia Wadelius and her associates will be analyzing a further score of genes that affect the uptake, transport, degradation, or effect of Warfarin.

“We want to develop clinical analyses that can predict what dosage of Warfarin a patient should have from the moment the drug is prescribed. If we can create such analyses, then we can reduce the risk of early bleeding. With the newly discovered gene and our findings, we are one step closer to a solution,” says Mia Wadelius.

Linda Nohrstedt | alfa
Further information:
http://www.uu.se
http://www.nature.com/tpj/index.html

More articles from Life Sciences:

nachricht Multi-institutional collaboration uncovers how molecular machines assemble
02.12.2016 | Salk Institute

nachricht Fertilized egg cells trigger and monitor loss of sperm’s epigenetic memory
02.12.2016 | IMBA - Institut für Molekulare Biotechnologie der Österreichischen Akademie der Wissenschaften GmbH

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

Im Focus: MADMAX: Max Planck Institute for Physics takes up axion research

The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.

The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...

Im Focus: Molecules change shape when wet

Broadband rotational spectroscopy unravels structural reshaping of isolated molecules in the gas phase to accommodate water

In two recent publications in the Journal of Chemical Physics and in the Journal of Physical Chemistry Letters, researchers around Melanie Schnell from the Max...

Im Focus: Fraunhofer ISE Develops Highly Compact, High Frequency DC/DC Converter for Aviation

The efficiency of power electronic systems is not solely dependent on electrical efficiency but also on weight, for example, in mobile systems. When the weight of relevant components and devices in airplanes, for instance, is reduced, fuel savings can be achieved and correspondingly greenhouse gas emissions decreased. New materials and components based on gallium nitride (GaN) can help to reduce weight and increase the efficiency. With these new materials, power electronic switches can be operated at higher switching frequency, resulting in higher power density and lower material costs.

Researchers at the Fraunhofer Institute for Solar Energy Systems ISE together with partners have investigated how these materials can be used to make power...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

UTSA study describes new minimally invasive device to treat cancer and other illnesses

02.12.2016 | Medical Engineering

Plasma-zapping process could yield trans fat-free soybean oil product

02.12.2016 | Agricultural and Forestry Science

What do Netflix, Google and planetary systems have in common?

02.12.2016 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>